The program of this 42nd edition has for main topics Covid and Tuberculosis and will address new diagnostic strategies.

Tuberculosis has been a major scourge since antiquity. The fight against this disease requires ever more efficient technologies. GenoScreen, a French biotech company, has recently developed a new weapon for predicting antibiotic resistance in the germs responsible for this disease. This new test, which comes in the form of a kit, quickly and efficiently detects the genetic mutations in the DNA of pathogenic germs and guides doctors in their medical prescriptions. This test is already being implemented in some thirty countries.

 Meet us at the 32th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) from April 23th to 26th in Lisbon, Portugal.

Press release - Researchers from GenoScreen and the Cardio-Thoracic Research Centre of Bordeaux (Inserm U1045) have demonstrated relationships between microorganisms in indoor air and those in asthmatic patients’ lungs. This work, published in the Journal of Allergy and Clinical Immunology and highlighted by the American Academy of Allergy, Asthma and Immunology (AAAI), also shows a variation in these micro- and mycobiota according to the patients’ inflammatory reaction type (T2 endotype).

Adebiotech is holding a new edition of its webinar dedicated to the applications of high throughput NGS sequencing on March 10th 2022.

This is confirmed by preliminary results of the PEOPLE study. This study is an opportunity for GenoScreen to apply its "Deeplex® Myc-Lep" sequencing assay for the first time to an international study.

GenoScreen and ScienceVision announce an agreement to commercialize the Deeplex® Myc-TB test in Malaysia, Myanmar and Brunei.

Following the Government's announcements concerning the COVID-19 pandemic, we are pleased to inform you that we have taken the necessary measures to ensure that all of our activities are maintained while guaranteeing the safety for our employees.

By continuing your visit to this site, you accept the use of statistics cookies